Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Arizona: - Cancer Center at Saint Joseph's — Phoenix, Arizona
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Arizona: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Arizona: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Arizona: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
- Ironwood Cancer & Research Centers — Goodyear, Arizona
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Arizona: - The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Arizona: - Mayo Clinic in Arizona - Phoenix ( Site 0044) — Phoenix, Arizona
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Arizona: - Arizona Clinical Trials — Chandler, Arizona
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Arizona: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Palo Verde Hematology Oncology — Glendale, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
- Ironwood Cancer & Research Centers — Goodyear, Arizona
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Arizona: - Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Arizona: - Mayo Clinic- Phoenix — Phoenix, Arizona
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Arizona: - Research Site — Phoenix, Arizona
Phase 3 Recruiting Academic/Other
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurr…
Sponsor: Mayo Clinic
NCT ID: NCT06205316
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 3 Recruiting Network
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The…
Sponsor: Proton Collaborative Group
NCT ID: NCT01492972
Sites in Arizona: - Mayo Clinic — Scottsdale, Arizona
Phase 2, Phase 3 Recruiting Academic/Other
To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery afte…
Sponsor: John Elfar
NCT ID: NCT03701581
Sites in Arizona: - University of Arizona — Tucson, Arizona
Phase 3 Recruiting Academic/Other
This phase III trial compares the effects of radiation therapy using RapidPlan, trademark, knowledge-based planning to human-driven planning in treating patients with prostate cancer. Radiation therapy uses high energy x-rays, particles, o…
Sponsor: Mayo Clinic
NCT ID: NCT06625034
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Arizona: - Kingman Regional Medical Center — Kingman, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Arizona: - Site US10011 — Tucson, Arizona
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Arizona: - Western Regional Medical Center - City of Hope Phoenix Goodyear — Goodyear, Arizona
- HonorHealth Research Institute — Scottsdale, Arizona
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
Phase 2 Recruiting Industry
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Sponsor: Syncromune, Inc.
NCT ID: NCT06533644
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sen…
Sponsor: Mayo Clinic
NCT ID: NCT06378866
Sites in Arizona: - Mayo Clinic in Arizona — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA positron emissi…
Sponsor: Mayo Clinic
NCT ID: NCT07025369
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Arizona: - Exelixis Clinical Site #67 — Phoenix, Arizona
- Exelixis Clinical Site #1 — Tucson, Arizona
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Arizona: - Banner-University Medical Center Tucson — Tucson, Arizona
- The University of Arizona Cancer Center-North Campus — Tucson, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- Arizona Urology Specialists, PLLC — Tucson, Arizona
Phase 1 Recruiting Industry
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…
Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona